Ocumension Therapeutics

SHSC:1477 Stock Report

Market Cap: HK$3.6b

Ocumension Therapeutics Future Growth

Future criteria checks 5/6

Ocumension Therapeutics is forecast to grow earnings and revenue by 101.9% and 39.3% per annum respectively. EPS is expected to grow by 101.8% per annum. Return on equity is forecast to be -0.3% in 3 years.

Key information

101.9%

Earnings growth rate

101.8%

EPS growth rate

Pharmaceuticals earnings growth11.1%
Revenue growth rate39.3%
Future return on equity-0.3%
Analyst coverage

Low

Last updated17 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SHSC:1477 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,429271167N/A3
12/31/2025887-511042383
12/31/2024470-232-7733
6/30/2024310-323-467-175N/A
3/31/2024278-351-503-176N/A
12/31/2023246-380-540-178N/A
9/30/2023227-399-561-223N/A
6/30/2023208-418-582-269N/A
3/31/2023184-411-546-235N/A
12/31/2022159-403-511-201N/A
9/30/2022124-393-615-165N/A
6/30/202290-383-720-129N/A
3/31/202273-322-791-163N/A
12/31/202156-260-862-197N/A
9/30/202144-426-760-232N/A
6/30/202132-593-659-267N/A
3/31/202123-1,429-588-240N/A
12/31/202013-2,265-517-213N/A
9/30/20208-2,540-407-173N/A
6/30/20202-2,816-297-133N/A
3/31/20201-2,064-203-120N/A
12/31/20190-1,312-109-108N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1477 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 1477 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 1477 is expected to become profitable in the next 3 years.

Revenue vs Market: 1477's revenue (39.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 1477's revenue (39.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1477 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 05:59
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocumension Therapeutics is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yanyin ZhuChina International Capital Corporation Limited
Fang QuanChina International Capital Corporation Limited
Ziyi ChenGoldman Sachs